Gara Jalqabaatti › Diffuse Large B-Cell Lymphoma › Tennessee › Nashville
Qorannoo klinikaalii Diffuse Large B-Cell Lymphoma Nashville, TN keessatti
Qorannoo 15 Diffuse Large B-Cell Lymphoma f Nashville fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Namoota walitti qabaa jiraSadarkaa 1/2
- Tennessee Oncology, Pllc Nashville, Nashville
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Namoota walitti qabaa jiraSadarkaa 2
- Vanderbilt University Medical Center, Nashville
Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma
Namoota walitti qabaa jiraSadarkaa 2
- Vanderbilt University/Ingram Cancer Center, Nashville
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Namoota walitti qabaa jiraSadarkaa 1/2
- SCRI Oncology Partners ( Site 0100), Nashville
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Namoota walitti qabaa jiraSadarkaa 2
- SCRI Oncology Partners ( Site 7002), Nashville
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Namoota walitti qabaa jiraSadarkaa 1
- SCRI Oncology Partners, Nashville
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Namoota walitti qabaa jiraSadarkaa 1
- Sarah Cannon Research Institute, Nashville
- Vanderbilt University Medical Center, Nashville
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Namoota walitti qabaa jiraSadarkaa 1
- Scri Oncology Partners, Nashville
- Vanderbilt Medical Center, Nashville
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
Namoota walitti qabaa jiraSadarkaa 2
- Tennessee Oncology, Nashville
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
Namoota walitti qabaa jiraSadarkaa 1/2
- Sarah Cannon Research Institute, Nashville
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Namoota walitti qabaa jiraSadarkaa 1/2
- Vanderbilt University Medical Center, Nashville
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Namoota walitti qabaa jiraSadarkaa 1/2
- TriStar BMT, Nashville
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Namoota walitti qabaa jiraSadarkaa 3
- SCRI Oncology Partners, Nashville
DALY II USA/ MB-CART2019.1 for DLBCL
Namoota walitti qabaa jiraSadarkaa 2
- SCRI Oncology Partners, Nashville
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Namoota walitti qabaa jiraSadarkaa 1
- Tennessee Oncology, Nashville
Qorannoo Diffuse Large B-Cell Lymphoma magaalota biroo keessatti
- New York City, NYQorannoo 21
- Baldwin Park, CAQorannoo 19
- Chicago, ILQorannoo 18
- Houston, TXQorannoo 17
- Los Angeles, CAQorannoo 17
- Milwaukee, WIQorannoo 16
- Boston, MAQorannoo 16
- Philadelphia, PAQorannoo 15
- Portland, ORQorannoo 15
- Durham, NCQorannoo 14
- Dallas, TXQorannoo 13
- Washington, DCQorannoo 12
Qorannoo biroo Nashville keessatti
- Kansara Qara'a Non-Small CellQorannoo 97
- Saree OljooQorannoo 81
- Kansara MetastatikiiQorannoo 70
- Kansarii ColorectalQorannoo 69
- Saree (Gosoota Hunda)Qorannoo 65
- Kansarii OvariiQorannoo 49
- Kansarii ProstateQorannoo 43
- Dhibee QaraQorannoo 40
- Kansa Selii Skwaamoo Mataa fi MormaQorannoo 39
- Kansarii PancreasQorannoo 39
- Kansa EndometiriyaaliiQorannoo 38
- MelanomaQorannoo 33
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.